title: New monoclonal antibodies on the horizon in multiple myeloma.
abstract: Across all cancers, monoclonal antibodies have emerged as a potential strategy for cancer therapy. Monoclonal antibodies target antigens expressed on the surface of cancer cells and accessory cells. This targeted approach uses the host's immune system to promote the killing of cancer cells. Multiple myeloma (MM) is the second most common hematologic malignancy that remains incurable in the majority of patients. The treatment of MM has evolved dramatically over the past decade and continues to evolve with the approval of four new drugs in 2015. Most recently the United States Food and Drug Administration (US FDA) approved two monoclonal antibodies for the treatment of this disease. Monoclonal antibodies are generally well-tolerated and offer a novel method of action for treated relapsed and refractory disease and are now being studied in the upfront setting. In this article, we review the evidence for the existing approved monoclonal antibodies and discuss promising targeted therapies and innovative strategies for the treatment of MM.
authors.affiliation: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
authors.forename: Elizabeth K
authors.initials: EK
authors.lastname: O'Donnell
authors.affiliation: Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Noopur S
authors.initials: NS
authors.lastname: Raje
keywords: monoclonal antibodies; multiple myeloma; novel therapies